Endothelin-1 inhibition by ambrisentan as a potential treatment adjunct after debulking surgery in epithelial ovarian cancer

Oncology Research

Volumn 17, Issue 8, 2009, Pages 383-386

  Kast, R E ^a  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

Ambrisentan; Endothelin; Epithelial ovarian cancer; Metaplasia; Micrometastases

Indexed keywords

AMBRISENTAN; ANTINEOPLASTIC AGENT; ENDOTHELIN 1; PHENYLPROPIONIC ACID DERIVATIVE; PYRIDAZINE DERIVATIVE;

ADJUVANT CHEMOTHERAPY; AMINO ACID SEQUENCE; ANIMAL; CHEMISTRY; DRUG ANTAGONISM; FEMALE; GYNECOLOGIC SURGERY; HUMAN; METHODOLOGY; MOLECULAR GENETICS; NEOPLASM; OVARY TUMOR; REVIEW;

AMINO ACID SEQUENCE; ANIMALS; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; ENDOTHELIN-1; FEMALE; GYNECOLOGIC SURGICAL PROCEDURES; HUMANS; MOLECULAR SEQUENCE DATA; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PHENYLPROPIONATES; PYRIDAZINES;

EID: 67650327639     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: 10.3727/096504009788428433     Document Type: Note

References (27)

1. Bagnato, A.; Rosano, L. Epithelial-mesenchymal transition in ovarian cancer progression: A crucial role for the endothelin axis. Cells Tissues Organs 185:85-94; 2007. (Pubitemid 46956847)
2. Rosano, L.; Spinella, F.; Di Castro, V.; Nicotra, M. R.; Dedhar, S.; de Herreros, A. G.; Natali, P. G.; Bagnato, A. Endothelin-1 promotes epithelial-to-mesenchymal transition in human ovarian cancer cells. Cancer Res. 65: 11649-11657; 2005. (Pubitemid 41821725)
3. Rosano, L.; Spinella, F.; Di Castro, V.; Dedhar, S.; Nicotra, M. R.; Natali, P. G.; Bagnato, A. Integrin-linked kinase functions as a downstream mediator of endothelin-1 to promote invasive behavior in ovarian carcinoma. Mol. Cancer Ther. 5:833-842; 2006.
4. Spinella, F.; Rosano, L.; Di Castro, V.; Natali, P. G.; Bagnato, A. Endothelin-1-induced prostaglandin E2-EP2, EP4 signaling regulates vascular endothelial growth factor production and ovarian carcinoma cell invasion. J. Biol. Chem. 279:46700-46705; 2004.
5. Del Bufalo, D.; Di Castro, V.; Biroccio, A.; Biroccio, A.; Salani, D.; Rosanò, L.; Spinella, F.; Bagnato, A. Endohypertenthelin- 1 acts as a survival factor in ovarian carcinoma cells. Clin. Sci. (Lond.) 103(Suppl. 48):302S-305S; 2002.
6. Spinella, F.; Rosano, L.; Di Castro, V.; Nicotra, M. R.; Natali, P. G.; Bagnato, A. Inhibition of cyclooxygenase-1 and -2 expression by targeting the endothelin-a receptor in human ovarian carcinoma cells. Clin. Cancer Res. 10: 4670-4679; 2004.
7. Rosano, L.; Di Castro, V.; Spinella, F.; Tortora, G.; Nicotra, M. R.; Natali, P. G.; Bagnato, A. Combined targeting of endothelin A receptor and epidermal growth factor receptor in ovarian cancer shows enhanced antitumor activity. Cancer Res. 67:6351-6359; 2007. (Pubitemid 47037518)
8. Rosano, L.; Di Castro, V.; Spinella, F.; Nicotra, M. R.; Natali, P. G.; Bagnato, A. ZD4054, a specific antagonist of the endothelin A receptor, inhibits tumor growth and enhances paclitaxel activity in human ovarian carcinoma vitro and in vivo. Mol. Cancer Ther. 6:2003-2011; 2007.
9. Barst, R. J. A review of pulmonary arterial hypertension: Role of ambrisentan. Vasc. Health Risk Manag. 3:11-22; 2007.
10. Newman, J. H.; Kar, S.; Kirkpatrick, P. Ambrisentan. Nat. Rev. Drug Discov. 6:697-698; 2007.
11. Vatter, H.; Seifert, V. Ambrisentan, a non-peptide endoendothelin receptor antagonist. Cardiovasc. Drug Rev. 24:63-76; 2006.
12. Spinella, F.; Rosano, L.; Di Castro, V.; Natali, P. G.; Bagnato, A. Endothelin-1 induces vascular endothelial growth factor by increasing hypoxia-inducible factor- 1alpha in ovarian carcinoma cells. J. Biol. Chem. 277: 27850-27855; 2002.
13. Spinella, F.; Rosano, L.; Elia, G.; Di Castro, V.; Natali, P. G.; Bagnato, A. Endothelin-1 stimulates cyclooxygen- ase-2 expression in ovarian cancer cells through multiple signaling pathways: Evidence for involvement of transactivation of the epidermal growth factor receptor. J. Cardiovasc. Pharmacol. 44:S140-S143; 2004.
14. Vacca, F.; Bagnato, A.; Catt, K. J.; Tecce, R. Transactivation of the epidermal growth factor receptor in endothelin- 1-induced mitogenic signaling in human ovarian carcinoma cells. Cancer Res. 60:5310-5317; 2000. (Pubitemid 30739794)
15. Sasaki, N.; Kudoh, K.; Kita, T.; Tsuda, H.; Furuya, K.; Kikuchi, Y. Effect of HER-2/neu overexpression on chemoresistance and prognosis in ovarian carcinoma. J. Obstet. Gynaecol. Res. 33:17-23; 2007.
16. Pils, D.; Pinter, A.; Reibenwein, J.; Alfanz, A.; Horak, P.; Schmid, B. C.; Hefler, L.; Horvat, R.; Reinthaller, A.; Zeillinger, R.; Krainer, M. In ovarian cancer the prognostic influence of HER2/neu is not dependent on the CXCR4/SDF-1 signaling pathway. Br. J. Cancer 96:485-491; 2007.
17. Del Bufalo, D.; Di Castro, V.; Biroccio, A.; Varmi, M.; Salani, D.; Rosanò, L.; Trisciuoglio, D.; Spinella, F.; Bagnato, A. Endothelin-1 protects ovarian carcinoma cells against paclitaxel-induced apoptosis: Requirement for Akt activation. Mol. Pharmacol. 61:524-532; 2002.
18. Salani, D.; Di Castro, V.; Nicotra, M. R.; Rosanò, L.; Tecce, R.; Venuti, A.; Natali, P. G.; Bagnato, A. Role of endothelin-1 in neovascularization of ovarian carcinoma. Am. J. Pathol. 157:1537-1547; 2000.
19. Rosano, L.; Varmi, M.; Salani, D.; Di Castro, V.; Spinella, F.; Natali, P. G.; Bagnato, A. Endothelin-1 induces tumor proteinase activation and invasiveness of ovarian carcinoma cells. Cancer Res. 61:8340-8346; 2001. (Pubitemid 33091630)
20. Ambrisentan (Letairis) for pulmonary arterial hypertenthelinsion. Med. Lett. Drugs Ther. 49:87-88; 2007.
21. Galie, N.; Badesch, D.; Oudiz, R.; Simonneau, G.; McGoon, M. D.; Keogh, A. M.; Frost, A. E.; Zwicke, D.; Naeije, R.; Shapiro, S.; Olschewski, H.; Rubin, L. J. Ambrisentan therapy for pulmonary arterial hypertension. J. Am. Coll. Cardiol. 46:529-535; 2005.
22. Billman, G. E. Ambrisentan (Myogen). Curr. Opin. Investig. Drugs 3:1483-1486; 2002.
23. Bagnato, A.; Catt, K. J. Endothelins as autocrine regulators of tumor cell growth. Trends Endocrinol. Metab. 9(9): 378-383; 1998.
24. Bagnato, A.; Rosanò, L. The endothelin axis in cancer. Int. J. Biochem. Cell Biol. 40(8):1443-1451; 2008.
25. Chiappori, A. A.; Haura, E.; Rodriguez, F. A.; Boulware, D.; Kapoor, R.; Neuger, A. M.; Lush, R.; Padilla, B.; Burton, M.; Williams, C.; Simon, G.; Antonia, S.; Sullivan, D. M.; Bepler, G. Phase I/II study of atrasentan, an endothelin A receptor antagonist, in combination with paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer. Clin. Cancer Res. 14(5):1464-1469; 2008.
26. Buckanovich, R. J.; Facciabene, A.; Kim, S.; Benencia, F.; Sasaroli, D.; Balint, K.; Katsaros, D.; O'Brien-Jenkins, A.; Gimotty, P. A.; Coukos, G. Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy. Nat. Med. 14(1):28-36; 2008.
27. Muntz, H. G.; Malpass, T. W.; McGonigle, K. F.; Robertson, M. D.; Weiden, P. L. Phase 2 study of intraperitoneal topotecan as consolidation chemotherapy in ovarian and primary peritoneal carcinoma. Cancer 113(3):490-496; 2008.